2017-04-10T18:55:20-05:00 2016-06-30 910189318 Moss Adams LLP 999 Third Avenue Suite 2800 Seattle WA 98104 990 2015-07-01 910961784 Seattle Biomedical Research Institute SEAT 2062567200 307 Westlake Avenue North No 500 Seattle WA 981095219 Kenneth Stuart President 2062567200 2017-03-23 1 Angela M Fidler P01254538 2063026500 2017-03-23 2015 2021-01-29 14:40:06Z Center for Infectious Disease Research Kenneth Stuart 307 Westlake Avenue North No 500 Seattle WA 981095219 72693508 0 X WWW.cidresearch.org X 1976 WA TO ELIMINATE THE WORLD'S MOST DEVASTATING INFECTIOUS DISEASES. 21 20 248 25 0 0 31681918 31026076 184105 183905 2635549 454415 1096900 33758578 35598472 65422974 0 461814 0 0 16268338 16242340 0 0 900292 18329696 19838472 34598034 36542626 1000438 28880348 46633100 38979993 8580767 6716119 38052333 32263874 X SEATTLE BIOMEDICAL RESEARCH INSTITUTE IS THE LARGEST NONPROFIT INDEPENDENT RESEARCH INSTITUTE IN THE WORLD FOCUSED SOLELY ON INFECTIOUS DISEASE RESEARCH. OUR MISSION IS TO ELIMINATE THE WORLD'S MOST DEVASTATING INFECTIOUS DISEASES. THE INSTITUTE INTEGRATES SYSTEMS BIOLOGY WITH MORE TRADITIONAL BIOLOGY TO DEVELOP A DEEPER UNDERSTANDING OF THE HUMAN IMMUNE SYSTEM AND INFECTIOUS DISEASE PATHOGENESIS. OUR RESEARCH PROGRAMS AIM TO MAKE TRANSFORMATIVE ADVANCES THAT PROVIDE A MORE COMPREHENSIVE EXPLANATION OF THE MYSTERIES OF THE INTERACTION BETWEEN PATHOGENS AND THE HUMAN IMMUNE SYSTEM THEREBY TO ACCELERATE PROGRESS ON THE DEVELOPMENTS OF VACCINES TO PREVENT AND DRUGS TO TREAT AND, WE HOPE ONE DAY, CURE INFECTIOUS DISEASES ULTIMATELY TO SAVE THE LIVES OF THE 14 MILLION PEOPLE WHO WILL OTHERWISE DIE EACH YEAR FROM MALARIA, HIV/AIDS, TUBERCULOSIS AND OTHER DREADED INFECTIOUS DISEASES. 0 0 20421420 461814 183905 WE CONDUCT FUNDAMENTAL INFECTIOUS DISEASE RESEARCH TO GENERATE CRITICAL NEW KNOWLEDGE ABOUT PATHOGENS AND THEIR INTERACTIONS WITH HUMANS TO ENABLE THE DISCOVERY AND DEVELOPMENT OF NOVEL INTERVENTIONS, RATIONAL VACCINES, THERAPEUTIC TARGETS, DRUGS AND DIAGNOSTICS. THESE DISEASES INCLUDE, BUT ARE NOT LIMITED TO, TUBERCULOSIS, MALARIA, AND HIV.WE ARE ALSO ENGAGED IN TRAINING THE NEXT GENERATION OF SCIENTISTS WHO WILL PERFORM SCIENTIFIC RESEARCH AND ADD CLINICAL CAPACITY THROUGHOUT THE WORLD.ACCOMPLISHMENTS INCLUDE: -DISCOVERY OF RNA EDITING, WHICH PROVIDES A POTENTIAL BASIS FOR DRUG TREATMENTS FOR THREE MAJOR PARASITIC DISEASES.-IDENTIFICATION OF TWO HIV1 ENVELOPE ANTIGENS THAT ELICITED BROADLY NEUTRALIZING ANTIBODIES AGAINST HIV WHEN INTRODUCED AS A TRIAL VACCINE IN PRIMATES.-GENETICALLY ENGINEERED THE MALARIA PARASITE P. FALCIPARUM BY THE PRECISE REMOVAL OF SPECIFIC GENES, CREATING A STRAIN THAT INFECTS HUMANS AND IS WELL TOLERATED BUT CANNOT CAUSE MALARIA, THUS MAKING IT A NOVEL NEW VACCINE CANDIDATE. 11993533 BIOQUEST: THE PRIMARY GOAL OF THE INSTITUTE'S SCIENCE OUTREACH PROGRAM, BIOQUEST, IS TO PROVIDE A CURRICULUM-RELEVANT, CAREER-INSPIRING, TECHNOLOGY-RICH SCIENCE EDUCATION PROGRAM WITHIN THE CONTEXT OF INFECTIOUS DISEASE RESEARCH TO HIGH SCHOOL STUDENTS, TEACHERS, AND THE GENERAL PUBLIC. WE ARE THE ONLY ORGANIZATION IN THE NATION TO OFFER A 32-PERSON TEACHING LAB, WITHIN THE FOOTPRINT OF AN INFECTIOUS DISEASE RESEARCH INSTITUTE. 32414953 1 1 0 0 0 0 0 0 0 0 1 0 0 0 1 1 1 0 0 0 1 0 0 0 1 0 0 1 0 1 0 0 0 1 0 0 0 0 0 0 0 0 0 0 0 0 0 1 51 0 1 248 0 0 0 0 0 0 1 1 0 0 0 0 X 21 20 0 0 0 0 0 0 0 1 1 0 0 1 1 1 1 1 1 1 1 1 1 X X Mistie Fain 2062567221 307 WESTLAKE AVE N 500 SEATTLE WA 981095219 Ken Stuart PhD President 3/9/16 - 6/30/16 40.00 X X 296272 0 50656 Alan Aderem PhD President thru 3/9/16/ Principal Inv 40.00 X X 328559 0 58546 Mark Ashida Chair/ Trustee 3.00 X X 0 0 0 Kevin Kelly JD Vice Chair/ Trustee 3.00 X X 0 0 0 Gregg Blodgett Treasurer/ Trustee 3.00 X X 0 0 0 Steven Clifford Secretary/ Trustee 3.00 X X 0 0 0 Trevor Moody Immediate Past Chair/ Trustee 3.00 X 0 0 0 Rosemary Barker Aragon Trustee 3.00 X 0 0 0 Patrice Auld Trustee 3.00 X 0 0 0 David Goesling Trustee 3.00 X 0 0 0 Irwin Goverman Trustee 3.00 X 0 0 0 John Kelly Trustee 3.00 X 0 0 0 Alan Levy PhD Trustee 3.00 X 0 0 0 Mark Mathewson Trustee 3.00 X 0 0 0 Neil McDonnell PharmD Trustee 3.00 X 0 0 0 Brian Olsavsky Trustee 3.00 X 0 0 0 Todd Patrick Trustee 3.00 X 0 0 0 TJ Petrizzo Trustee 3.00 X 0 0 0 Brian Schwartz Trustee 3.00 X 0 0 0 David R Stewart JD Trustee 3.00 X 0 0 0 Rob Thomas Trustee 3.00 X 0 0 0 Moya Vazquez Trustee 3.00 X 0 0 0 John D Aitchison Chief Scientific Officer 24.00 X 169102 0 23295 Louis Coffman Sr VP-Strategy/Bus. Dev. thru 7/1/16 40.00 X 343270 0 54913 Stefan Kappe PhD Principal Investigator 40.00 X 207356 0 46996 Peter Myler PhD Principal Investigator 40.00 X 171786 0 33195 Ronald C Hood Director of IT 40.00 X 181826 0 36538 David R Sherman Principal Investigator 40.00 X 161692 0 46496 Kevin B Urdahl Associate Professor 40.00 X 150972 0 13900 Leon E Jenkins II VP Institutional Advancement & Chief Public Affair 40.00 X 146517 0 7761 Joseph D Smith Associate Professor 40.00 X 146306 0 16377 2303658 0 388673 27 0 1 0 UNIVERSITY OF WASHINGTON GRANTS & CONTRA 12455 COLLECTIONS DRIVE CHICAGO IL 60693 RESEARCH 1560208 BERYLLIUM DISCOVERY CORP 3 PRESTON COURT BEDFORD MA 01730 RESEARCH 1504894 FRED HUTCHINSON CANCER RESEARCH CENTER 1100 FARIVIEW AVE N SEATTLE WA 98109 RESEARCH 1218614 INSTITUTE FOR SYSTEMS BIOLOGY 401 TERRY AVE N SEATTLE WA 98109 RESEARCH 868944 Daniel J Edelman Inc 21992 Network Place ChicAGO IL 60673 Communications 749908 21 222518 22761077 8042481 31026076 RESEARCH SUPPORT Svcs 541900 176773 176773 PROGRAM SERVICE FEES 541900 7132 7132 183905 602146 602146 2541566 2702144 -160578 -160578 -160578 3800000 3943333 4398 -143333 -4398 -147731 -147731 82480 222518 620659 -538179 -538179 1075 0 1075 1075 WESTLAKE LLC 900099 34456260 34456260 34456260 65422974 183905 0 34212993 250000 250000 211814 211814 2353195 1143394 1209801 10582058 10096566 436886 48606 783978 700743 51560 31675 1580971 1356166 168430 56375 942138 807549 113368 21221 67482 10402 53748 3332 57877 52614 4936 327 30684 30684 1662064 1330578 184999 146487 30696 23554 2087 5055 352209 297292 29017 25900 646884 534431 79688 32765 4538021 3619351 548453 370217 215153 196082 17335 1736 179050 117901 44392 16757 1417096 1312307 62560 42229 179028 77567 96549 4912 SUBCONTRACTS 6503973 6503973 RESEARCH SUPPLIES 3229198 3223275 3536 2387 Postage/Bank/Fees/Dues 413390 313834 89052 10504 LAB/CLINICAL/TECH SVS 313386 235560 300 77526 2281 2281 36542626 32414953 3227381 900292 900 900 7477919 3288839 5132568 6096219 87320 25077 82353 71374 683015 783974 23959363 17442465 7220423 6516898 25766290 22196712 182312 0 46633100 38979993 3620735 3641491 4765557 2071772 194475 1002856 8580767 6716119 X 37381411 31661355 670922 602519 38052333 32263874 46633100 38979993 X 28880348 -193478 -34475329 X 0 1 X 1 1 1 X UNIVERSITY OF WASHINGTON MEDICAL CENTER SEATTLE WA OREGON HEALTH SCIENCE UNIVERSITY PORTLAND OR RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED 11549090 7109310 4439780 11553031 9550058 2002973 857242 783097 74145 6516898 DEFERRED RENT LIABILITY 693356 Security Deposits - Subtenants 309500 1002856 X 34055783 -193478 2702144 2508666 31547117 33875857 33875857 65422974 39844242 2711642 2711642 37132600 -589974 -589974 36542626 Part X, Line 2: The Center follows the provisions of authoritative guidance relating to accounting for uncertain tax positions. The Agency recognizes the tax benefit from uncertain tax positions only if it is more likely than not that the tax positions will be sustained on examination by the tax authorities, based on the technical merits of the position. The tax benefit is measured based on the largest benefit that has a greater than 50% likelihood of being realized upon ultimate settlement. The Center recognizes interest and penalties related to income tax matters in income tax expense. As of June 30, 2016 and 2015, the Center had no uncertain tax positions requiring accrual. Part XI, Line 2d - Other Adjustments: Rental Expenses 2,702,144. Part XI, Line 4b - Other Adjustments: BOOK/TAX DIFFERENCE ON INVESTMENT IN 307 WESTLAKE 34,475,329. Loss from Sale of Assets -9,498. Special event Expenses -620,659. Investment Expenses 30,685. Part XII, Line 2d - Other Adjustments: Rental Expenses 2,702,144. Loss from Sale of Assets 9,498. Part XII, Line 4b - Other Adjustments: Special Event Expenses -620,659. Investment Expenses 30,685. East Asia and the Pacific 0 0 Program Services Travel/Meeting/Conference 12042 East Asia and the Pacific 0 0 Program Services Sub-Award 17303 Europe (Including Iceland & Greenland 0 0 Program Services Travel/Meeting/Conference 32972 Europe (Including Iceland & Greenland) 0 0 Program Services Sub-Award 36454 Europe (Including Iceland & Greenland) 0 0 Program Services Research 68259 North America (Canada and Mexico) 0 0 Program Services Travel/Meeting/Conference 1074 North America (Canada and Mexico) 0 0 Program Services Research 5148 Sub-Saharan Africa 0 0 Program Services Travel/Meeting/Conference 2983 Sub-Saharan Africa 0 0 Program Services Sub-Award 31643 Sub-Saharan Africa 0 0 Program Services Research 3293 South America 0 0 Program Services Travel/Meeting/Conference 643 0 0 0 0 0 0 176235 35579 211814 0 0 0 0 0 0 Part I, line 3: SEATTLE BIOMEDICAL RESEARCH INSTITUTE DOES NOT MAINTAIN ANY FOREIGN OFFICES. THE INSTITUTE'S SUB-CONTRACTORS ARE PERFORMING RESEARCH ON BEHALF OF THE ORGANIZATION AROUND THE WORLD, THE ACCRUAL METHOD OF ACCOUNTING IS USED TO ACCOUNT FOR EXPENDITURES. GALA Sponsorship 304998 222518 82480 25845 284368 77500 232946 304998 222518 82480 25845 284368 77500 232946 620659 -538179 0 One Reel 911 East Pike Suite 206 Seattle WA 98122 237246862 501(c)(3) 250000 BUMBERSHOOT SPONSORSHIP 1 X 0 1 X X X 1 0 0 0 0 0 0 0 0 Ken Stuart PhD President 3/9/16 - 6/30/16 296272 0 0 0 0 0 26200 0 24456 0 346928 0 0 0 Alan Aderem PhD President thru 3/9/16/ Principal Inv 328559 0 0 0 0 0 26500 0 32046 0 387105 0 0 0 John D Aitchison Chief Scientific Officer 169102 0 0 0 0 0 16800 0 6495 0 192397 0 0 0 Louis Coffman Sr VP-Strategy/Bus. Dev. thru 7/1/16 343270 0 0 0 0 0 26500 0 28413 0 398183 0 0 0 Stefan Kappe PhD Principal Investigator 207356 0 0 0 0 0 19333 0 27663 0 254352 0 0 0 Peter Myler PhD Principal Investigator 171786 0 0 0 0 0 16999 0 16196 0 204981 0 0 0 Ronald C Hood Director of IT 181826 0 0 0 0 0 18000 0 18538 0 218364 0 0 0 David R Sherman Principal Investigator 161692 0 0 0 0 0 16000 0 30496 0 208188 0 0 0 Kevin B Urdahl Associate Professor 150972 0 0 0 0 0 13313 0 587 0 164872 0 0 0 Leon E Jenkins II VP Institutional Advancement & Chief 146517 0 0 0 0 0 7305 0 456 0 154278 0 0 0 Joseph D Smith Associate Professor 146306 0 0 0 0 0 14562 0 1815 0 162683 0 0 0 Part I, Line 1a FIRST CLASS TRAVEL IS PERMITTED IF ALLOWABLE UNDER AN AWARD AND/OR THE DIFFERENTIAL IN PRICE IS PAID FOR OUT OF NON-GRANT FUNDS. Part I, Line 4a LOUIS COFFMAN RECEIVED A SEVERANCE PAYMENT OF $249,818.52 DURING THE YEAR ENDED 6/30/16. He departed on July 1, 2016. STEFAN KAPPE part V Part V X 80000 71374 0 1 1 71374 Part II Stefan Kappe is employed as a principal investigator for the entity. The purpose of the loan is not restricted to a specific purpose. Form 990, Part VI, Section A, line 1 THE BOARD CAN DELEGATE AUTHORITY TO THE EXECUTIVE COMMITTEE OR OTHER SUBCOMMITTEES (E.G. FINANCE) HOWEVER MOST DECISIONS COME TO THE FULL BOARD FOR ACTION AFTER VETTING AT THE COMMITTEE LEVEL. THERE ARE NO MATERIAL DIFFERENCES AMONG MEMBERS OF THE BOARD. THERE ARE TWO NON-INDEPENDANT VOTING MEMBERS OF THE BOARD WHO ARE TRUSTEES. Form 990, Part VI, Section B, line 11 THE RETURN WILL BE REVIEWED IN DETAIL BY THE controller. IN ADDITION, THE 990 WILL BE PRESENTED TO THE FINANCE AND AUDIT COMMITTEE. A FINAL DRAFT WILL BE ELECTRONICALLY SENT TO ALL TRUSTEES OF THE INSTITUTE. OUR BOARD LIAISON WILL MONITOR THE DISTRIBUTION OF THE RETURN AND WILL COLLECT COMMENTS AND RESPONSES AND REPORT THESE TO THE DIRECTOR OF FINANCE PROMPTLY. ANY PERTINENT RESPONSES WILL BE ADDRESSED AND RESOLVED BEFORE THE FINAL TAX RETURN IS FILED. Form 990, Part VI, Section B, line 12c EACH TRUSTEE (AND ALL KEY EMPLOYEES) AND MEMBERS OF A COMMITTEE WITH BOARD DELEGATED POWERS SHALL ANNUALLY SIGN A STATEMENT WHICH AFFIRMS THAT SUCH PERSON HAS RECIEVED A COPY OF THE CONFLICT OF INTEREST POLICY, HAS READ AND UNDERSTANDS THE POLICY, AND AGREES TO COMPLY WITH THE POLICY. IF ANY KNOW CONFLICTS ARISE, THEY ARE SENT TO THE EXECUTIVE COMMITTEE FOR RESOLUTION. A FOLLOWUP TO THE LEADERSHIP TEAM THEN OCCURS, IF NEEDED. PROCEDURE: 1. DUTY TO DISCLOSE: IN CONNECTION WITH ANY ACTUAL OR POSSIBLE CONFLICT OF INTEREST, AN INTERESTED PERSON MUST DISCLOSE THE EXISTANCE AND NATURE OF HIS/HER FINANCIAL INTEREST TO THE EXECUTIVE COMMITTEE OF THE BOARD OF TRUSTEES PRIOR TO CONSIDERATION OF THE PROPOSED TRANSACTION OR ARRANGEMENT AND MUST NOT ENTER INTO ANY ARRANGEMENT WHERE THERE IS AN ACTUAL OR POTENTIAL CONFLICT OF INTEREST WITHOUT EXECUTIVE COMMITTEE APPROVAL. 2. DETERMINING WHETHER A CONFLICT OF INTEREST EXISTS: AFTER DISCLOSURE OF THE FINANCIAL INTEREST, THE INTERESTED PERSON SHALL RECUSE HIMSELF/HERSELF WHILE THE FINANCIAL INTEREST IS DISCUSSED AND VOTED UPON. THE EXECUTIVE COMMITTEE SHALL DECIDE IF A CONFLICT OF INTEREST EXISTS. 3. PROCEDURES FOR ADDRESSING THE CONFLICT OF INTEREST: A. THE EXECUTIVE COMMITTEE SHALL, IF APPROPRIATE, APPOINT A DISINTERESTED PERSON OR COMMITTEE TO INVESTIGATE ALTERNATIVES TO THE PROPOSED TRANSACTION OR ARRANGEMENT. B. AFTER EXERCISING DUE DILLIGENCE, THE BOARD OR COMMITTEE SHALL DETERMINE WHETHER SEATTLE BIOMED CAN OBTAIN A MORE ADVANTAGEOUS TRANSACTION OR ARRANGEMENT WITH REASONABLE EFFORTS FROM A PERSON OR ENTITY THAT WOULD NOT GIVE RISE TO A CONFLICT OF INTEREST. C. IF A MORE ADVANTAGOUS TRANSACTION OR ARRANGEMENT IS NOT REASONABLY ATTAINABLE UNDER CIRCUMSTANCES THAT WOULD NOT GIVE RISE TO A CONFLICT OF INTEREST, THE BOARD OR COMMITTEE SHALL DETERMINE BY A MAJORITY VOTE OF THE DISINTERESTED MEMBERS WHETHER THE TRANSACTION OR ARRANGEMENT IS IN THE INSTITUTE'S BEST INTEREST AND FOR ITS OWN BENEFIT AND WHETHER THE TRANSACTION IS FAIR AND REASONABLE TO THE INSTITUTE AND SHALL MAKE ITS DECISION AS TO WHETHER TO ENTER INTO THE TRANSACTION OR ARRANGEMENT IN CONFORMITY WITH SUCH DETERMINATION. 4. VIOLATIONS OF THE CONFLICTS OF INTEREST POLICY: A. IF THE BOARD, A COMMITTEE, THE INSTITUTE'S STAFF OR A TRUSTEE HAS REASONABLE CAUSE TO BELIEVE THAT A TRUSTEE OR A COMMITTEE MEMBER HAS FAILED TO DISCLOSE AN ACTUAL OR POSSIBLE CONFLICT OF INTEREST, IT SHALL INFORM THE MEMBER OF THE BASIS FOR SUCH BELIEF AND AFFORD THE MEMBER THE OPPORTUNITY TO EXPLAIN THE ALLEGED FAILURE TO DISCLOSE. B. IF, AFTER HEARING THE RESPONSE OF THE MEMBER AND MAKING SUCH FURTHER INVESTIGATION AS MAY BE WARRANTED IN THE CIRCUMSTANCES, THE EXECUTIVE BOARD DETERMINES THAT THE MEMBER HAS, IN FACT, FAILED TO DISCLOSE AN ACTUAL OR POSSIBLE CONFLICT OF INTEREST, IT SHALL TAKE APPROPRIATE DISCIPLINARY AND CORRECTIVE ACTION. Form 990, Part VI, Section B, line 15 COMPENSATION PLANNING AND REVIEW TAKES PLACE ANNUALLY. HUMAN RESOURCES PROVIDES MARKET DATA FOR EACH POSITION IN THE INSTITUTE. FOR SENIOR LEADERSHIP POSITIONS, SPECIFICALLY KEY EMPLOYEES, AN OUTSIDE COMPENSATION CONSULTANT BENCHMARKS THESE POSITIONS AND PROVIDES DATA AND ANALYSIS, WHICH ALLOWS THE ORGANIZATION'S HUMAN RESOURCE DEPARTMENT TO ESTABLISH A PAY RANGE FOR EACH OF THESE ROLES AT OUR INSTITUTE. THE HUMAN RESOURCE DEPARTMENT ALSO GATHERS INDUSTRY-SPECIFIC INFORMATION FROM OUR PEERS TO VALIDATE THE SURVEY INFORMATION AND TO ENSURE THAT WE REMAIN COMPETITIVE WITH OUR COMPENSATION. THIS INFORMATION IS SOMETIMES GATHERED FROM LOCAL PEER ORGANIZATIONS IN OUR INDUSTRY AND/OR FROM PEER ORGANIZATIONS WHO ARE PART OF THE ASSOCIATION OF INDEPENDENT RESEARCH INSTITUTES (AIRI). THE MOST RECENT COMPENSATION REVIEW OF SENIOR POSITIONS (PRIOR TO JUNE 30, 2016) TOOK PLACE IN JANUARY 2012. Form 990, Part VI, Section C, line 19 THE GOVERNING DOCUMENTS, CONFLICT OF INTEREST POLICY, AND FINANCIAL STATEMENTS ARE AVAILABLE UPON REQUEST. Form 990, Part XI, line 9: BOOK/TAX DIFFERENCE ON INVESTMENT IN 307 WESTLAKE -34,475,329.